MiNK Therapeutics (INKT) Expected to Announce Quarterly Earnings on Tuesday

MiNK Therapeutics (NASDAQ:INKT) will likely be posting its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect MiNK Therapeutics to post earnings of ($0.68) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 12:30 PM ET.

MiNK Therapeutics Stock Down 5.3%

INKT stock opened at $9.74 on Monday. The stock has a market capitalization of $45.68 million, a PE ratio of -3.21 and a beta of 0.35. MiNK Therapeutics has a 52 week low of $6.34 and a 52 week high of $76.00. The firm has a 50 day moving average of $11.54 and a 200 day moving average of $12.67.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, January 19th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $35.00.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC boosted its holdings in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,247 shares of the company’s stock after purchasing an additional 1,441 shares during the period. Geode Capital Management LLC owned about 0.30% of MiNK Therapeutics worth $159,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 2.87% of the company’s stock.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.